Elucid
Elucid, founded in Boston, develops non-invasive medical software for cardiovascular disease diagnosis.
Profile
Elucid develops AI-powered software to diagnose and characterize cardiovascular disease using non-invasive imaging.
Elucid, founded in Boston, develops non-invasive medical software for cardiovascular disease diagnosis. The company’s flagship product, PlaqueIQ™, leverages CT Virtual Histology™ to quantify plaque morphology, validated against tissue specimens. This FDA-cleared and CE-marked software uniquely characterizes plaque biology at the cellular level, enabling physicians to predict heart attack risks and tailor treatments.
Elucid raised $27 million in a Series B funding round in June 2022, led by an undisclosed strategic investor, with participation from Biovision Ventures and existing investors like MedTex Ventures and BlueStone Venture Partners. The company’s technology is designed to address the gap in early detection of atherosclerosis, a leading cause of cardiovascular disease. Elucid’s software is commercially available in the U.S., Europe, and South Korea, targeting healthcare providers seeking precision medicine tools.
Recent developments focus on expanding its commercial reach and advancing applications like fractional flow reserve (FFRct) and virtual transcriptomics. Despite its innovative approach, Elucid faces challenges in scaling adoption and navigating reimbursement complexities in diverse healthcare markets.
Who buys this
- Healthcare providers specializing in cardiology
- Hospitals and medical centers
- Diagnostic imaging facilities
- Cardiovascular researchers
- Insurance companies evaluating diagnostic tools
Strengths and what to watch
Strengths
- FDA-cleared and CE-marked software validated against histopathology
- Unique ability to quantify plaque morphology at the cellular level
- Strong backing from strategic investors and venture capital firms
Watch for
- Challenges in scaling adoption across diverse healthcare markets
- Dependence on reimbursement approvals for Medicare and other payors
- Competition from established players in cardiovascular diagnostics
Key Information
- Founded
- 2013
- Headquarters
- Boston
Frequently Asked Questions
What does Elucid do?
Elucid develops AI-powered software for diagnosing cardiovascular disease using non-invasive imaging. Their flagship product, PlaqueIQ™, quantifies plaque morphology at the cellular level, helping physicians predict heart attack risks and tailor treatments. The software is FDA-cleared and CE-marked.
What is PlaqueIQ™?
PlaqueIQ™ is Elucid’s FDA-cleared and CE-marked software that uses CT Virtual Histology™ to quantify plaque morphology. It uniquely characterizes plaque biology at the cellular level, validated against tissue specimens, enabling precise cardiovascular disease diagnosis and personalized treatment planning.
Who uses Elucid’s software?
Elucid’s software is used by healthcare providers specializing in cardiology, hospitals, diagnostic imaging facilities, cardiovascular researchers, and insurance companies evaluating diagnostic tools. It targets precision medicine applications for early detection and treatment of cardiovascular disease.
How is Elucid funded?
Elucid raised $27 million in a Series B funding round in June 2022, led by an undisclosed strategic investor. Biovision Ventures, MedTex Ventures, and BlueStone Venture Partners also participated, supporting the commercialization of their innovative cardiovascular diagnostic technology.
What are Elucid’s challenges?
Elucid faces challenges in scaling adoption across diverse healthcare markets, navigating reimbursement complexities, and competing with established players in cardiovascular diagnostics. Their success depends on Medicare and other payor approvals for broader adoption.
Where is Elucid’s software available?
Elucid’s software is commercially available in the U.S., Europe, and South Korea. It targets healthcare providers seeking precision medicine tools for early detection and treatment of cardiovascular disease, with ongoing efforts to expand its global reach.
Sources
- www.prnewswire.com — Series B funding round details and product capabilities
- elucid.com — Product information and company overview
- www.prnewswire.com — Context on medical diagnostics market
- www.viz.ai — Competitive landscape in AI-powered cardiovascular diagnostics